| |||||||||||||
| |||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin HydrochlorideTablets, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg.|
|
|
|
Home |
Shares |
F&O |
Mutual Funds |
Loans |
Insurance |
News Centre Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Advertise © All rights reserved. IRIS Business Services Limited A Disclaimer |
| |||||||||||||
| |||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
|
|
|
|
Home |
Shares |
F&O |
Mutual Funds |
Loans |
Insurance |
News Centre Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Advertise © All rights reserved. IRIS Business Services Limited A Disclaimer |